# Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT

> **NCT02876679** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 94 (actual)

## Conditions studied

- Graft vs Host Disease

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Anti-Thymocyte Globulin
- **DRUG:** Conditioning regimen

## Key facts

- **NCT ID:** NCT02876679
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-06
- **Primary completion:** 2020-10-12
- **Final completion:** 2020-10-12
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2020-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02876679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02876679, "Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02876679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*